The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...

Acrivon Therapeutics, Inc. (NASDAQ: ACRV), a clinical stage biopharmaceutical company with a market capitalization of $184 million and an impressive 60% stock return over the past year, announced that ...

Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of ...

Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy ...

SeaStar Medical plans to conduct an interim analysis at the trial’s 90-day primary endpoint with the first 100 subjects. Given the current pace of enrollment, the company anticipates a Data Safety ...

is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its innovative “Wave” device. Additionally, CergenX has been accepted into the ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation to CergenX’s AI-powered tool for neonatal brain scans. The Irish startup will now be in line for prioritised ...

With further refinement, the enzyme could be adapted for even more complex reactions, making it a valuable tool in drug development, agricultural chemicals, and materials science. “The possibilities ...

GSK5764227 has been granted FDA breakthrough therapy designation, potentially expediting its development as a treatment for relapsed/refractory osteosarcoma. The FDA has granted breakthrough therapy ...

Overall survival rates among patients treated with the drug were 25% higher. Prof James Catto from the University of Sheffield described the findings as a "major breakthrough" in treating bladder ...

The table below is a review of notable updates that occurred in December 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.